RT @BIGagainstBC@twitter.com

#SABCS2022 Stop by poster P5-14-01 to learn about transcriptomic insights into #lobular #breastcancer from the largest gene expression dataset of patients enrolled in a #clinicaltrial with centrally-assessed lobular #BC - a retrospective analysis of the #MINDACT trial.

🐦🔗: https://twitter.com/BIGagainstBC/status/1600988890621419520

RT @double_whammied@twitter.com

Thanks @DrJoeUnger@twitter.com @fredhutch@twitter.com for this crucial research into barriers to #BIPOC #clinicaltrial participation. All you gotta do is ask, folks!!!

Good to see it being emphasized here at #SABCS2022 https://twitter.com/ErikaHamilton9/status/1600230711088119809

🐦🔗: https://twitter.com/double_whammied/status/1600597193483726848

RT @DrYukselUrun@twitter.com

🔶Adjuvant abemaciclib reduces the risk of recurrence in patients with hormone receptor (+), HER2(-), node-positive, high-risk early #BreastCancer
🔶Serious AEs 15·5%
🔶Most common G 3–4 AE neutropenia 19·6%
@OncoAlert@twitter.com @SABCSSanAntonio@twitter.com #SABCS #SABCS2022
https://doi.org/10.1016/S1470-2045(22)00694-5

🐦🔗: https://twitter.com/DrYukselUrun/status/1600233075455143937

RT @stolaney1@twitter.com

Will ctDNA be able to help us tailor post-preop therapy in breast cancer?

@melindatelli@twitter.com #SABCS2022 @OncoAlert@twitter.com

🐦🔗: https://twitter.com/stolaney1/status/1600132267309174784